Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF‐β expression and connective tissue features
Santhi K. Ganesh(University of Michigan), Nazli B. McDonnell(National Institute on Aging), Kristina L. Hunker(Michigan Medicine), Benjamin F. Griswold(National Institute on Aging), Lan Tong(University of Michigan), Florian Schoenhoff(University Hospital of Bern), Clair A. Francomano(Indiana University – Purdue University Indianapolis), Harry C. Dietz(Johns Hopkins University), Min‐Lee Yang(University of Michigan), Leslie Sloper(National Institute on Aging), Rafi Raza(National Institute on Aging), Shinie Kuo(University of Michigan), Dianna M. Milewicz(The University of Texas Health Science Center at Houston), Jiandong Yang(National Institute on Aging), Rachel Morissette(National Institute on Aging), Xu Zhi(Kunming Institute of Zoology), Jennifer E. Van Eyk(Cedars-Sinai Smidt Heart Institute)
Cited by 83
Related Papers
The 2017 international classification of the Ehlers–Danlos syndromes
|American Journal of Medical Genetics Part C Seminars in Medical Genetics|2017|1.9k
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2
|Nature Genetics|2005|1.8k
Genome-wide association study of blood pressure and hypertension
|Nature Genetics|2009|1.4k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
|New England Journal of Medicine|2008|839